Cocaine use disorder is a chronic relapsing condition characterized by compulsive drug seeking and taking even after prolonged abstinence periods. Subsequent exposure to drug-associated cues can promote intense craving and lead to relapse in abstinent humans and rodent models. The responsiveness to these cocaine-related cues, or 'cue reactivity', can trigger relapse and cocaine-seeking behaviors; cue reactivity is measurable in cocaine-dependent humans as well as rodent models. Cue reactivity is thought to be predictive of cocaine craving and relapse. Here we report that PPARγ agonism during abstinence from cocaine self-administration reduced previously active lever pressing in Sprague Dawley rats during cue-reactivity tests, while administration of the PPARγ antagonist, GW9662, reversed this effect. PPARγ agonism also normalized nuclear ERK activity in the medial prefrontal cortex and hippocampus which was reversed with GW9662. Our results support the utility of PPARγ agonism as a relapse prevention strategy to maintain abstinence in the presence of cocaine-associated cues.
INTRODUCTION
Cocaine use disorder is associated with emotional and cognitive impairments accompanied by dysfunctional behaviors that engender susceptibility to relapse (Goldstein & Volkow 2002) . Even after long durations of abstinence, relapse to cocaine-seeking and -taking can be triggered by exposure to drug-associated contexts and stimuli (e.g. paraphernalia) which evoke conditioned physiological and subjective effects as well as appetitive approach behaviors ('cue reactivity') via activated limbiccorticostriatal circuits (for review, see Weiss et al., 2001) . Recent studies suggest that cue reactivity escalates during abstinence and predicts relapse in cocaine-dependent subjects (Bedi et al. 2011; Moeller et al. 2013b; Moeller et al. 2013a; Wang et al. 2013) . In rodent models, cue reactivity (assessed by lever presses reinforced by the discrete cocaine-paired cue complex) escalates across months of forced abstinence (FA) from self-administration (SA) (Ghitza et al. 2003; Grimm et al. 2001; Neisewander et al. 2000) . This escalation of cue reactivity evolves within the framework of long-term neuroadaptations in which extracellular signal-regulated kinase (ERK) signaling in limbic-corticostriatal circuits plays an important role (Koya et al. 2009; Lu et al. 2005; Lu et al. 2007; McGinty et al. 2010; McGinty et al. 2015; Sun et al. 2013; Whitfield et al. 2011) . ERK is a key mediator of the cell cycle, cell maturation and differentiation; in the CNS, it mediates several forms of plasticity, learning and memory (Sweatt 2004) .
We have recently discovered that activated, phosphorylated ERK (pERK) and the nuclear receptor and transcription factor peroxisome proliferator activated receptor gamma (PPARγ) directly interact in a dynamic multiprotein complex that facilitates ERK-dependent memory consolidation within the hippocampus (HIP) (Jahrling et al. 2014) . The compelling interrelationship between pERK and PPARγ engages induction of PPARγ-and ERK-dependent transcriptomes and a proteome that alleviated synaptic and network abnormalities (Denner et al. 2012; Jahrling et al. 2014; Nenov et al. 2014; Rodriguez-Rivera et al. 2011) . These findings prompted the current hypothesis that PPARγ modulates ERK to attenuate cue reactivity during late FA from cocaine SA (Anastasio et al. 2014b; Anastasio et al. 2014a; Nielsen et al. 2012; Swinford-Jackson et al. 2016 ).
The work herein shows that PPARγ agonism with the FDA-approved drug pioglitazone (PIO) significantly attenuated both behavioral sensitization to cocaine and cue reactivity in late FA without affecting general locomotor activity or motivation for the natural reward sucrose; this outcome was accompanied by normalization of pERK levels in the medial prefrontal cortex (mPFC), HIP, amygdala (AMG) and nucleus accumbens (NAc), important nodes in the limbic-corticostriatal circuit which mediate cocaine-related behaviors (Everitt & Wolf 2002; Koob & Le Moal 2001; Koob & Nestler 1997) . The selective PPARγ antagonist GW9662 reversed both the behavioral and molecular effects of PPARγ agonism. Coimmunoprecipitated pERK and PPARγ and their association in mPFC and HIP were reciprocally modulated with PPARγ agonism and antagonism. These findings indicate that, in an analogous manner to memory consolidation processes in HIP (Jahrling et al. 2014) , PPARγ agonism resolves dysregulated pERK to ameliorate cue reactivity in late FA. Thus, a PPARγ agonist may be a useful therapeutic approach to counteract cue reactivity and extend abstinence.
MATERIALS AND METHODS

Animals
Experimentally naïve, male Sprague-Dawley rats (n = 143; Harlan, Inc.) weighing approximately 225 g (7-8 weeks of age) upon arrival were allowed to acclimate for 5-7 days in a colony room with controlled temperature (21-23°C) and humidity (45 weeks50 percent) on a 12-hour light dark cycle (on between 0700 and 1900 hours). Rats were housed two per cage with food and water ad libitum. All experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) and with the approval of the Institutional Animal Care and Use Committee at the University of Texas Medical Branch (UTMB).
Drugs and treatments
(À)-Cocaine (National Institutes on Drug Abuse) was dissolved in sterile 0.9 percent NaCl. The PPARγ agonist PIO (Actos®) was obtained from the UTMB pharmacy. Via contract with a certified provider (Bio-Serve), PIO was milled into standard rodent chow at a dosage of 50 mg/kg, as previously described (Denner et al. 2012; Jahrling et al. 2014; Nenov et al. 2014; Rodriguez-Rivera et al. 2011) . Food was weighed and replenished daily. Rats' weight and food intake was monitored throughout the experiments in which treatment ensued and PIO had no effect on body weight or food intake (Supplementary Fig. 1 ). Pair-housed rats received the same treatment. While we cannot determine individual dosage or individual food intake, both rats had access ad libitum and, again, no difference between treatment groups (pair-housed cages) was noted. Sucrose pellets were purchased from BioServ (45 mg/pellet). GW9662 (Sigma) was dissolved in 100 percent DMSO.
Behavioral sensitization to cocaine
Up to this point, PPARγ agonism has been explored as affecting alcohol intake (Blednov et al. 2015; Ferguson et al. 2014; Stopponi et al. 2013) , opioid consumption (de Guglielmo et al. 2015) , morphine tolerance (de Guglielmo et al. 2014) and behavioral sensitization to methamphetamine (Maeda et al. 2007 ) and cannabinoids (Enayatfard et al. 2013) . Behavioral sensitization to psychostimulants is a noncontingent drug exposure paradigm designed to model the long-lasting behavioral and neurochemical adaptations that underlie enhanced locomotor behavior in response to repeated psychostimulant exposure. Here, we evaluated the effects of PIO on the development of cocaine sensitization. Four days prior to initiating the behavioral sensitization protocol, PIO treatment was started based on pilot studies showing that four days of PIO intake is required to achieve steady-state effects on CNS PPARγ DNA binding activity ( Supplementary Fig. 2 ). Locomotor activity was monitored and quantified under low light conditions using a modified open field system (San Diego Instruments). Clear Plexiglas chambers (40 × 40 × 40 cm) were surrounded by a 4 × 4 photobeam matrix positioned 4 cm from the chamber floor. Vertical activity was also recorded using a row of photobeams positioned approximately 16 cm above the chamber floor. The control software counted total horizontal activity as well as vertical beam interruptions and stored the counts in 5-minute bins; these data are reported as total ambulation (De La Garza & Cunningham 2000; Lee et al. 1991; McCreary et al. 1999; Paris et al. 1991; Sell et al. 2002) .
Rats were randomly assigned to untreated and PIOtreated groups yielding four experimental groups (n = 6/ group): (1) saline untreated; (2) saline PIO-treated; (3) cocaine untreated; and (4) cocaine PIO-treated. Each rat was habituated daily for 1 hour in the locomotor chamber for four days prior to intraperitoneal (IP) injection of cocaine (15 mg/kg) or saline (1 ml/kg). Immediately after cocaine injection, each rat was returned to the locomotor chamber for a 1-hour locomotor activity assessment. This process was repeated once a day for five days. All groups then underwent a seven-day withdrawal period during which time they remained in their home cages but were handled and weighed daily. After seven days of withdrawal, all rats were exposed to the locomotor chamber for 1 hour prior to cocaine challenge (15 mg/kg, IP) and locomotor assessment.
Cocaine self-administration
Implantations of intravenous catheters with back mounts were performed under anesthesia with a cocktail containing xylazine (8.6 mg/kg), acepromazine (1.5 mg/kg) and ketamine (43 mg/kg) in bacteriostatic saline. The catheter was inserted into the right jugular vein and exited dorsally (Anastasio et al. 2014a; Anastasio et al. 2014b; Nielsen et al. 2012) . Daily catheter flushes were performed to ensure catheter patency using a solution of 0.1-ml bacteriostatic saline and heparin sodium salt (10 U/ml; American Pharmaceutical Partners), streptokinase (0.67 mg/ml; Sigma) and ticarcillin disodium (66.67 mg/ml; Research Products International). Following catheter surgery, rats were allowed at least five days of recovery before initiation of SA training. In all experiments, a control group was included in which saline was delivered upon active lever pressing.
Cocaine SA took place in standard operant chambers housed within ventilated, sound-attenuating chambers (Med-Associates, Inc.). Each chamber was equipped with a pellet receptacle flanked by two retractable levers, a stimulus light above each response lever, and a houselight opposite the levers. Cocaine infusions were delivered via syringe attached to an infusion pump (Med-Associates) mounted outside the cubicle. The infusion pumps were connected to the catheters via liquid swivels (Instech, Plymouth Meeting, PA) and polyethylene tubing encased inside a metal spring leash (Plastics One, Roanoke, VA). Cocaine SA training consisted of 14 daily 180-minute sessions during which rats were trained to lever press for cocaine infusions (0.75 mg/kg/0.1 ml infusion) (Anastasio et al. 2014a; Anastasio et al. 2014b; Nielsen et al. 2012) . Schedule completions on the active lever resulted in delivery of a cocaine infusion over a 6-second period paired simultaneously with illumination of the house and stimulus lights and activation of the infusion pump (discrete cue complex paired with cocaine delivery); inactive lever presses produced no scheduled consequences. Following cocaine delivery, the stimulus light and infusion pump were inactivated; the house light remained on for an additional 20 seconds to indicate a timeout period during which lever presses had no scheduled consequences. Rats were trained on a fixed ratio (FR) 1 schedule of reinforcement and progressed to an FR5 schedule, with stability defined upon achieving seven infusions/hour on the FR5 with less than 10 percent variability in infusions for three consecutive days.
As a control for subsequent neurochemical studies, we included a 'no cue reactivity test' group of rats which were trained to SA cocaine then split into two treatment groups, PIO or untreated, and subjected to 30 days FA then sacrificed in an identical manner as cohorts that underwent cocaine cue reactivity testing.
Sucrose self-administration
Sucrose SA training consisted of 14 daily 180-minute sessions during which freely fed rats were trained to lever press for 45-mg sucrose pellets (Bio-Serv) (Cunningham et al. 2011a) . Experimental parameters were identical to those employed in cocaine SA training except that sucrose was substituted as the reinforcer.
Note: After either cocaine or sucrose SA acquisition and maintenance, rats were divided into treatment groups balanced for infusions and drug/natural reward intake during SA acquisition and maintenance then subjected to 30-day FA followed by cue reactivity tests, described in detail in the 'Self-Administration Research Design' section following.
Self-administration research design
Experiment 1 Effect of PPARγ agonism on cue reactivity.
Using a 2 × 2 factorial design, two separate cohorts of rats were trained to either SA cocaine or saline then pseudorandomly divided (balanced for lever pressing and drug intake) into four treatment groups to test the effect of PIO on cue reactivity following cocaine or saline SA: (1) Saline untreated (n = 12); (2) saline PIO-treated (n = 10); (3) cocaine untreated (n = 20); and (4) cocaine PIOtreated (n = 22). PIO treatment began following the final session of cocaine SA and continued during the 30-day FA period. Food intake and body weight were monitored weekly during the 30-day treatment/FA period; no significant differences in either parameter were measured in any of the treatment groups (data not shown).
Following 30 days of FA, the four groups were subjected to cue reactivity testing by quantifying active and inactive lever presses during a 60-minute session. Presses on the previously active lever were reinforced by the discrete cue complex (stimulus light illuminated, pellet dispenser activated) on an FR1 schedule; presses on the inactive lever were recorded but produced no scheduled consequences.
Experiment 2 Effect of PPARγ antagonism on PIO attenuation of cue reactivity. Following cocaine SA, rats were pseudo-randomly divided (balanced for lever pressing/drug intake) into four treatment groups using a 2 × 2 factorial design to test the effect of the specific and irreversible PPARγ antagonist GW9662, on PIO attenuation of cue reactivity: (1) cocaine untreated (n = 8); (2) cocaine untreated + GW9662 (n = 10); (3) cocaine PIO-treated (n = 9); and (4) cocaine PIO-treated + GW9662 (n = 9). PIO treatment began following the final session of cocaine SA and continued during the 30-day FA period. Following 30 days of FA, the four groups were subjected to cue reactivity testing by quantifying active and inactive lever presses during a 60-minute session. Treatment groups designated to receive GW9662 received an IP injection 2 hours prior to cue reactivity testing based upon timing of previous studies (Denner et al. 2012; Jahrling et al. 2014) . During the test, presses on the previously active lever were reinforced by the discrete cue complex (stimulus light illuminated, pellet dispenser activated) on an FR1 schedule; presses on the inactive lever were recorded but produced no scheduled consequences.
Experiment 3 Effect of PPARγ agonism on acquisition of
sucrose SA and cue reactivity. Rats (n = 28) were trained to SA sucrose pellets (45 mg/pellet, BioServ) as above (Cunningham et al., 2011) followed by 30 days of FA and a 60-minute cue reactivity test on day 44. Three treatment groups were included: (1) untreated (n = 9); (2) PIO-treated during days 1-14 during acquisition of sucrose SA (n = 9); and (3) PIO-treated during days 15-44 of FA (n = 10). Rats were allowed food and water ad libitum.
To assess cue reactivity, presses on the previously active lever were reinforced by the discrete cue complex (stimulus light illuminated, pellet dispenser activated) on an FR1 schedule during the 60-minute session; presses on the inactive lever were recorded but produced no scheduled consequences.
We also included a set of 'no cue reactivity test' rats that were killed upon removal from their home cages on FA Day 30 without re-exposure to the operant chambers to control for the behavioral experience during the cue reactivity session for the ex vivo neurochemical studies.
Immunoblot
Immediately following cue testing, rats were anesthetized, decapitated and brains immediately microdissected on ice for À80°C storage following flash freezing in liquid nitrogen. Following the procedure described by Heffner et al. (1980) , we collected the following brain regions from coronal sections prepared using a rat brain slicing guide (Zivic Instruments): dorsomedial prefrontal cortex, amygdala, dorsal hippocampus, ventral tegmental area and the nucleus accumbens. After rinsing with ice cold PBS, we sliced first at optic chiasm, two in front (every other 2-mm slot), four behind (every other slot) to generate six 2-mm coronal sections sandwiched between seven blades. After arranging sections on filter paper soaked with ice cold PBS, chosen brain regions were collected.
We also included a set of 'no cue reactivity test' rats that were killed immediately upon removal from their home cages on FA Day 30 without re-exposure to the operant chambers to control for the behavioral experience during the cue reactivity session for the ex vivo neurochemical studies. Thus, reported changes in protein expression or phosphorylation state represent cue-induced alterations in PPARγ and ERK. Nuclear extracts were prepared according to manufacturer's instructions (Activ Motif) followed by BCA protein assay (Thermo Scientific, #23225) then stored frozen at À80°C.
As a control for subsequent ex vivo neurochemical studies, a set of 'no cue reactivity test' rats were analyzed to control for the behavioral experience during the cue reactivity session. These rats were trained to SA cocaine then were killed immediately upon removal from their home cages on FA Day 30 without re-exposure to the operant chambers.
Nuclear samples (20 μg) were thawed on ice, resolved by SDS-PAGE (7.5 percent Bio-Rad Mini-PROTEAN TGX) and electro-blotted onto PVDF membranes (Immobilon, Millipore). To quantitatively compare between immunoblot film bands, a crude whole-brain lysate (20 μg/well) prepared from Sprague-Dawley rat brains was included in triplicate on each gel as an internal standard (further described below). After 15 minutes in TBS-T (50 mM Tris pH 7.5, 150 mM NaCl, 0.05 percent Tween-20) blocking buffer supplemented with 2 percent ECL Advance Blocking agent (GE Healthcare), membranes were incubated overnight at 4°C with the antibody PPARγ (1:500; Millipore, 07-466), and for 1 hour with the following antibodies: ERK (1:1000; Cell Signaling, 9102), and pERK (1:1000; Cell Signaling, 9101). Lamin-A/C (1:1000; Santa Cruz, SC-20681) was used as a loading control for nuclear fractions. All antibodies were diluted in TBS-Tween blocking buffer with 2 percent ECL Advance Blocking agent (GE Healthcare). After five washings with TBS-Tween, the blots were incubated for 1 hour at room temperature with anti-mouse IgG conjugated with horseradish peroxidase (1:50,000; GE Healthcare, NA931V) or anti-rabbit IgG conjugated with horseradish peroxidase (1:50 000; GE Healthcare, NA934V), in TBS-Tween containing 2 percent ECL Advance Blocking agent. After five washings with TBS-Tween, protein bands were detected by chemiluminescence via Advance ECL (GE Healthcare) detection system in accordance with the manufacturer's instructions. Films exposed in the linear range for the antibody combinations employed were developed with a Kodak imager.
As previously published by us (Jahrling et al. 2014) , film exposures of immunoblot membranes were scanned at 300 dpi, and numeric band density and background values were acquired using ImageJ software [National Institutes of Health (NIH)]. The numeric values for lamin A/C in the loading control from each of the three identical rat brain homogenate internal standards were averaged, and all samples run on the gel were normalized to the loading control average density value. Lamin A/C was chosen as a normalization value so that density values for the loading control would remain in the linear range of the samples we were investigating. A standard loading control such as actin would have generated a signal too intense to accurately quantify the PPARγ and pERK. Thus, this method allows for more precise comparison between different gels and across different experiments. In all instances, the total ERK signal was unchanged and was not reported. Immunoblot bands shown represent the mean of each experimental group and were cropped from contiguous lanes from a single immunoblot probed sequentially for PPARγ, pERK and lamin A/C then stripped and probed for total ERK. All samples were run at least three times and averaged prior to calculating group means and SEMs; film exposure times between experimental repeats were controlled with a stopwatch yet films in the linear range for the primary and secondary antibody combination (determined empirically) were the overall objective. Thus, the histograms in Figs 4, 5 and 6 represent the group population mean of the total number of animals for each SA/FA/cue reactivity experiment normalized to lamin A/C of a rat brain crude homogenate. We analyzed a cohort of 'no cue reactivity test' rats that were killed immediately upon removal from their home cages on FA Day 30 without re-exposure to the operant chambers to compare our sham and
Immunoprecipitation
PPARγ and ERK protein complexes were immunoprecipitated according to Jahrling et al. (2014) . Briefly, tissue extract buffer (25-μM HEPES, 0.1 M Triton X-100, 1 M glycerol and ddH 2 O supplemented with 0.02 M Sigma protease inhibitor cocktail (P8340), 0.02 M NaF and 0.02 M sodium orthovanadate) was combined with nuclear extract prepared from 600-μg wet weight starting material. Six hundred microgram input was determined as optimal by performing input-output curves as demonstrated in Jahrling et al. (2014) ; 0-μg input served as negative control and immunoblot of the unbound fraction determined the IP efficiency~50 percent. A 500-μl reaction volume was put into a 1.5-ml Eppendorf tube followed by PPARγ polyclonal antibody (10-μl, Millipore 07-466) then incubated overnight on a rotating rocker at 4°C. The following day, Protein A sepharose beads 20 μl (Cell Signaling) were added and samples placed on a rotating platform at 4°C for an additional 3 hours. Samples were centrifuged at 3000 ×g for 1 minute and supernatant carefully removed and discarded. Pelleted beads were washed by adding 500 μl of extract buffer and placed on a rotating rocker in 4°C for 20 minutes; washes were repeated four times. After the final centrifugation, the supernatant was removed without removing pelleted beads and 3× SDS PAGE sample buffer was added. Samples were heated to 95-100°C for 5 minutes then allowed to cool to room temperature. Samples were then centrifuged (14 000 ×g) for 1 minute and supernatant was loaded onto a 7.5 percent SDS-PAGE gel (Biorad), electrophoresed, then transferred onto PVDF membranes (Immobilon, Millipore). After 15 minutes in TBS-T (50 mM Tris pH 7.5, 150 mM NaCl, 0.05 percent Tween-20) blocking buffer supplemented with 2 percent ECL Advance Blocking agent (GE Healthcare), membranes were incubated overnight at 4°C with the following antibodies: PPARγ-HRP (1:1000; Novus Biologicals, NBP2-22106H), then pERK-HRP (1:1000; Cell Signal, 8544 seconds) then quantified as described previously to a standard control loaded in triplicate (Jahrling et al. 2014) .
Statistical analyses
Statistical power analyses (SAS for Windows, Version 6.12, SAS Institute) on previous cocaine SA data (Anastasio et al. 2014b; Cunningham et al., 2011; Cunningham et al. 2013; Nic Dhonnchadha et al. 2009; Nielsen et al. 2012 ) indicated that at least n = 8 rats/group is required to achieve 95 percent confidence against type 1 error at p = 0.05. Therefore, all SA experiments were carried forth with a minimum group size of n = 8 rats per group.
Data are reported as mean +/À SEM. Two-factor (treatment × drug) ANOVA was employed to determine group differences (treatment [e.g. PPARγ] × drug [e.g. cocaine]) as well as treatment × drug interaction, followed by Tukey to detect pairwise differences. Where appropriate, repeated measures two-way ANOVA was used to analyze whether treatment or drug influenced the primary outcome measure as well as whether an interaction occurred (e.g. treatment × drug). The experimenter was blinded to the group allocation (e.g. PIO treatment) throughout the duration of the study. Statistics are reported in the figure legends and additional tables.
RESULTS
PPARγ agonism blocks development of behavioral sensitization to cocaine. A previous study showed that PPARγ agonism with PIO or rosiglitazone during the withdrawal period attenuated methamphetamine induced locomotor sensitization (Maeda et al. 2007) . We therefore tested the hypothesis that PIO would prevent the development of cocaine-induced locomotor sensitization. In contrast to Maeda et al. (2007) , we began PIO treatment four days prior to the experiment. Cocaine (15 mg/kg) evoked hyperactivity relative to saline treated rats. PIO-treated rats exhibited stabile cocaine-evoked hyperactivity across the five days of cocaine delivery (Fig. 1a) as well as following a challenge injection delivered after seven days of withdrawal (Fig. 1b) . Thus, PIO tempered behavioral sensitization to cocaine.
PPARγ agonism with pioglitazone attenuated cue reactivity following prolonged abstinence from cocaine selfadministration. The first cohort of rats (Fig. 2a) acquired cocaine SA to stability (Fig. 2b ) and then were assigned to PIO or untreated groups to balance for active lever presses during cocaine SA. Immediately following the last SA session, treatment groups were placed on either PIO treatment (50 mg of PIO/kg chow) or untreated. PIO delivered in rat chow activates brain PPARγ without altering food intake, body weight or locomotor activity ( Fig. 1; Supplementary Fig. 1 ), consistent with our previous work (Rodriguez-Rivera et al. 2011). Following 30 days of FA, cue reactivity was assessed. As expected, saline-SA groups exhibited low pressing for the previously active lever that was unaffected by PIO treatment (Fig. 2c) . Animals trained to SA cocaine and left untreated during FA displayed high levels of lever pressing for cocaine-associated cues. PIO-treated rats exhibited significantly fewer previously active lever presses during the cue reactivity test compared to the untreated cocaine SA group. Finally, inactive lever presses (Fig. 2c, inset) and latency to lever press were unaffected by any of our treatments (data not shown).
PPARγ agonism had no effect on sucrose intake or cue reactivity. Because we are ultimately interested in neural mechanisms specific to re-exposure to cocaine context and cues following chronic cocaine SA and FA, we included saline SA above as a control for un-reinforced lever pressing. We next tested if SA of a 'natural' reinforcer (e.g. sucrose pellets) is affected by PPARγ agonism with PIO. Rats were trained to SA sucrose pellets under the same contingency schedule as cocaine (refer to SA Methods; Fig. 3a) . We found that PIO treatment, during acquisition (Days 1-14) did not alter sucrose intake (Fig. 3b) . PIO treatment during 30 days of FA (Days 14-44) did not affect cue reactivity in rats trained to SA sucrose (Fig. 3c ) and inactive lever pressing was unaltered across groups (Fig. 3c, inset) . Because PPARγ agonism prevented behavioral sensitization to cocaine yet had no effect on acquisition of sucrose SA or cue reactivity to this natural reward, we conclude that, under the present experimental conditions, PPARγ agonism exerted a selective influence on limbic-corticostriatal circuit function dysregulated by the psychostimulant cocaine.
PPARγ agonism counteracted reductions in nuclear PPARγ and pERK following cue reactivity test. Nuclear extracts of brain regions involved in cue reactivity circuitry were subjected to immunoblot (IB) to measure PPARγ and active ERK (pERK) in individual rats (Anastasio et al. 2014b; Anastasio et al. 2014a ) using established methods (Jahrling et al. 2014) . While ERK1 has been shown to mediate cocaine-induced alterations in the striatum (Ferguson et al. 2006; Mazzucchelli et al. 2002) , we measured the more abundant ERK2 isoform in the brain Figure 1 PPARγ agonism blocks the development and expression of behavioral sensitization to cocaine. Untreated or PIO-treated rats were injected (IP) with saline (sham) or cocaine over 5 days followed by locomotor activity assessment (a). Repeated measures two-way ANOVA detected a significant effect of time [****p < 0.0001; F(4,76) = 6.26] and treatment [p < 0.0001; F(3,19) = 287] as well as an interaction [p < 0.0001; F(12,76) = 10.2] on cocaine-evoked locomotor activity. (b) Following 7-day abstinence, all rats received a cocaine challenge injection prior to assessment of locomotor activity; two-way ANOVA detected a significant effect of PIO treatment [*****p < 0.0001; F(3,15) = 18.2]. Data is expressed as mean +/À SEM regions studied. ERK2 has been shown to dominate in the types of behavior we are measuring (Fijal et al. 2015; Girault et al. 2007; Velazquez et al. 2013) . Furthermore, ERK1 phosphorylation changes tracked with ERK2 ( Supplementary Fig. 3 ).
When exposed to the cocaine SA chamber and allowed to lever press for cocaine-associated cues, the cocaine untreated group, which displayed the highest levels of cue reactivity (Fig. 2c, 2d) , exhibited attenuated pERK and PPARγ levels in PFC, HIP and AMG compared to all other groups (Fig. 4a, b, c) . The NAc of cocaine untreated SA rats exhibited decreased nuclear PPARγ but no change in pERK; however, nuclear pERK in cocaine PIO-treated rats was decreased relative to all other groups (Fig. 4d) . In all instances, the total ERK protein signal in nuclear extracts was unchanged. Importantly, 'no cue reactivity test' rats taught to SA cocaine with or without PIO treatment during 30 days of FA, exhibited similar levels of PPARγ, ERK1/2 and pERK1/2 in all brain regions interrogated (Supplementary Fig. 4) . Thus, lever pressing for cocaine-associated cues induced a rapid reduction of nuclear pERK and PPARγ in PFC, HIP and AMG that was counteracted by PPARγ agonism during FA. Furthermore, comparable samples from the brains of rats trained to SA sucrose (Fig. 3 ) exhibited no alterations in nuclear ERK, pERK or PPARγ ( Supplementary Fig. 5 ), suggesting that the observed changes in the brains of rats trained to SA cocaine are because of chronic cocaine SA and FA rather than effects of lever pressing during the cue reactivity test. Taken together, one hypothesis is that PPARγ agonism counteracts loss of 'top down' control over cocaine cue reactivity, possibly by preventing ERK dysregulation in the PFC, HIP, AMG and NAc, during prolonged abstinence.
PPARγ antagonism reversed effects of PIO treatment on cue reactivity and nuclear PPARγ and pERK in PFC and HIP, but not AMG or NAc. To demonstrate the necessity of PPARγ in suppression of cue reactivity, we employed the specific and irreversible antagonist, GW9662, as previously described (Denner et al. 2012; Jahrling et al. 2014) . In the present experiment, we injected GW9662 or vehicle (IP) two hours prior to the cue reactivity test. As before, PIO-treated rats trained to cocaine SA demonstrated suppressed cue reactivity compared to cocaine untreated rats (Fig. 5a ). Cocaine untreated rats injected Figure 2 PPARγ agonism attenuated cue reactivity following prolonged abstinence from cocaine self-administration. (a) Experimental timeline for 14 days cocaine self-administration (SA) followed by 30-day forced abstinence (FA), and cue reactivity test on day 44. (b) Rats were trained to self-administer cocaine during daily 3-hour sessions. Cocaine was initially delivered on a fixed ratio-1 (FR1) schedule of reinforcement until meeting criterion; then, FR5 schedule was introduced. (c) After 14 days of cocaine SA and 30 days of FA, rats were subject to a 60-minute cue reactivity test. Two-way ANOVA and Tukey multiple comparison tests showed that PPARγ agonism significantly decreased active lever pressing in the cocaine PIO-treated group compared to the cocaine untreated group. F(1,58) = 18.39 **p = 0.004. A main effect of cocaine was noted as well F(1,58) = 267.0 ****p < 0.0001. Arrow: inactive lever pressing was unaffected by either drug or treatment. (d) A separate cohort of rats were subjected to cue reactivity tests on day 44, after 30 days of FA, under three conditions: within the context alone, followed by our standard cue reactivity test, then in response to IP cocaine (15 mg/kg, IP). (e) PIO treatment attenuated active lever pressing in the context (left), in the presence of cocaine cues (center), and cocaine primed cocaine seeking (right). *p < 0.05, **p < 0.01, Student's two-sided t-test. Data is reported as mean +/À SEM with either vehicle or GW9662 showed equivalent cue reactivity as did PIO-treated rats injected with GW9662, suggesting that acute GW9662 reversed the effect of PIO treatment; GW9662 alone had no effect on lever presses for cocaine-associated cues and inactive lever pressing was unchanged across groups (Fig. 5a,  inset) . As a control, we tested whether IP GW9662 (1 mg/kg) affected locomotor activity and found that total ambulations were unaltered by IP injection of GW9662 (Supplementary Fig. 6 ).
We next investigated the status of PPARγ and ERK in PFC, HIP, AMG and NAc with IB to find that PPARγ antagonism, which blocks PIO-mediated suppression of cue reactivity, reversed the effects of PIO on nuclear PPARγ and pERK in PFC and HIP (Fig. 5b, 5c ), but not in the AMG or NAc (Supplementary Fig. 7 ). This finding indicates that PPARγ agonism influences cue reactivity in the PFC and/or HIP whereas PPAR activity AMG and NAc does not appear to mediate lever pressing behavior to cocaine-associated cues.
pERK:PPARγ protein complexes are increased by exposure to cocaine-associated cues in PIO-treated rats; PPARγ antagonism reversed PIO effects. Based on our previous work showing that nuclear PPARγ-pERK protein complexes facilitate ERK-dependent memory consolidation (Jahrling et al. 2014) , we co-immunoprecipitated (IPed) nuclear PPARγ-pERK complexes and found that PPARγ-pERK complexes track with immunoblot (IB) results in PFC and HIP and that the irreversible PPARγ antagonist GW9662 reversed both PIO-mediated suppression of cue reactivity and alterations in PPARγ and pERK within the PFC and HIP (Fig. 6a, 6b) . Last, while IB of AMG and NAc nuclear extracts revealed cocaine and PIO-mediated changes, PPARγ antagonism failed to reverse these effects, and we observed no effect of GW9662 on PPARγ-pERK complexes ( Supplementary  Fig. 7 ).
DISCUSSION
Drug-induced neuroadaptations within the limbic corticostriatal system are postulated to underlie cocaine craving and relapse (Everitt & Wolf 2002; Koob & Le Moal 2001; Koob & Nestler 1997; Marchant et al. 2015) . Clinical studies in cocaine-dependent subjects reveal reduced PFC cerebral blood flow and metabolic activity, as well as loss of grey and white matter integrity that accompany enhanced reactivity to cocaine-associated cues, impaired decision-making and impulsivity (Dias et al. 2015; Fein et al. 2002; Franklin et al. 2002; Lane et al. 2010; Ma et al. 2009; Ma et al. 2014a; Ma et al. 2015 Volkow et al. 1988; Volkow et al. 1992) . Rodent models for cocaine SA and FA show these same deficits both structurally (Ma et al. 2014b; Narayana et al. 2014) and behaviorally (Anastasio et al. 2014b; Anastasio et al. 2014a; Fijal et al. 2015; Pickens et al. 2011; Swinford-Jackson et al. 2016) and thus are an ideal model to study the biochemical mechanisms that underlie cue reactivity and risk for relapse in cocainedependent humans.
We used cue reactivity to test the efficacy of PPARγ agonism during FA in reducing previously active lever pressing when rats are subsequently re-exposed to the context and cues previously associated with cocaine SA Figure 4 PPARγ agonism counteracted cue reactivity reductions in nuclear PPARγ and pERK2. Immediately following the cue reactivity test (Fig. 1c) , rats were euthanized and brain regions of interest sub-dissected and processed for immunoblot analysis. Exposure to cues associated with cocaine SA led to rapid changes in nuclear PPARγ (left) and phosphorylated, therefore activated, ERK2 (pERK, right) in (a) medial prefrontal cortex (PFC); (b) hippocampus (HIP); (c) amygdala (AMG); (d) nucleus accumbens (NAc). PPARγ agonism (PIO) prevented these changes in PFC, HIP and AMG. In the NAc, PPARγ agonism and exposure to cues associated with cocaine SA led to rapid nuclear PPARγ protein increase and nuclear pERK reduction. No significant changes were found in total nuclear ERK in any of the brain regions tested. *p < 0.05, **p < 0.01, ***p < 0.001. because cocaine cue reactivity predicts relapse and treatment success in cocaine dependent subjects (Carter & Tiffany 1999; Rohsenow et al. 1990) . PPARγ agonism has previously been used in models of behavioral sensitization to methamphetamine (Maeda et al. 2007) , opioid consumption (de Guglielmo et al. 2015) and alcohol drinking and relapse (Stopponi et al. 2011; Stopponi et al. 2013) . These studies found a main effect of PPARγ agonism on consumption, with a specific effect on stress-induced relapse to alcohol rather than cue-induced relapse. To date, the utility of PPARγ agonism in cocaine relapse had not been investigated. We found that treatment with the potent and selective PPARγ agonist, PIO, administered throughout the cocaine FA period, significantly attenuated active lever pressing upon re-exposure to drug cues. Furthermore, delivery of the specific and irreversible antagonist, GW9662, prior to the cue reactivity test reversed the effects of PIO treatment on previously active lever pressing. Given the extensive differences between experimental design, animal strain and drug substance utilized in the previous reports, it is difficult to predict if PIO treatment would affect cocaine SA, as is the case for alcohol and opioids (de Guglielmo et al. 2015) . However, our data thus far support PPARγ as a viable therapeutic target to attenuate drug-seeking behavior to help maintain abstinence. Figure 5 PPARγ antagonism reversed effects of PIO treatment on cocaine seeking behavior and blocked PIO-mediated cue reactivity effects on nuclear PPARγ and pERK2 in PFC and HIP. Two hours prior to the cue reactivity test rats were injected with either 1 mg/kg GW9662 or vehicle (DMSO). (a) PIO treatment suppressed cocaine seeking behavior as previously (black bar), whereas GW9662 reversed PIO effects on lever pressing to cues associated with cocaine (light grey bar). Two-way ANOVA F(1,30) = 9.35 p = 0.005. **p < 0.01 compared to all other groups, Tukey multiple comparisons. No significant effect of drug or treatment on inactive lever pressing, inset. Immunoblot on brain regions collected immediately after the cue reactivity test revealed that GW9662 reversed PIO-mediated changes in nuclear PPARγ (left) and pERK2 (right) in (b) medial prefrontal cortex (PFC) and (c) hippocampus (HIP). No significant changes were found in AMG or NAc and total nuclear ERK2 in any of the brain regions tested was unaltered. **p < 0.01; ns, not significant. In support of this, PIO treatment prevented pERK reductions in nuclear fractions from PFC, HIP and AMG (no change in total ERK). Within nuclear fractions of the NAc, re-exposure to cocaine cues and context resulted in reduced pERK whereas in untreated rats trained to SA cocaine, nuclear pERK remains unaltered (compared to saline controls) in the NAc. These results indicate that re-exposure to cocaine-associated context and cues drives the loss of nuclear ERK activity in PFC, HIP and AMG whereas PIO treatment during cocaine FA protects from this loss. We make these assertions because rats that were not re-exposed to cocaine-associated cues, with or without PIO treatment, exhibited no alterations in PPARγ, ERK or ERK phosphorylation.
It is important to note, however, that while GW9662 PPARγ antagonism reversed the behavioral effect of PIO on cocaine cue reactivity, GW9662 reversed the biochemical effects of PIO only in the PFC and HIP. Thus, PPARγ regulation of ERK and ERK-dependent behaviors is limited to the PFC and HIP and further suggests that the HIP also performs an important role in cocaineseeking behavior in addition to the PFC. For example, in tests targeting context-dependent cue reactivity, previous work established overlapping neural substrates within the PFC, HIP and AMG (Fuchs et al. 2005 ). The HIP is clearly an important element of this circuit contributing to neuroadaptations resulting from repeated exposure to a cocaine-paired context in the absence of discrete cocaine cues (Ito et al. 2008; Tropea et al. 2008) . Thus, we put forth the hypothesis that HIP ERK and PPARγ are mechanistically involved in cocaine-seeking behavior triggered by cocaine-associated cues in addition to the well-established PFC ERK system (reviewed in McGinty et al., 2015) . Future studies testing the effect of GW9662 delivery to HIP versus PFC on previously active lever pressing to cocaine-paired cues in PIO-treated rats may reveal important mechanisms on cocaine-seeking behavior. Furthermore, our strategy to begin PIO treatment early in the withdrawal phase is supported by several previous studies utilizing strategies to activate ERK in PFC (e.g. BDNF; Berglind et al. 2007; Berglind et al. 2009; Sun et al. 2013; Whitfield et al. 2011) and likely contributed to treatment efficacy and may have implications for treatment strategies in humans trying to maintain abstinence.
On another note, the relatively rapid (~2-hour pretreatment) reversal of PIO effects on cue reactivity with GW9662 antagonism and co-IP of these two proteins suggests that PPARγ dynamically regulates ERK activity. This concept is supported by our studies on HIPdependent memory consolidation (Denner et al. 2012; Jahrling et al. 2014 ) in which we found that PPARγ agonism enhanced ERK-dependent cognitive performance via an increase in PPARγ-pERK protein complexes during memory consolidation and 'acute' GW9662 PPARγ antagonism both prevented memory consolidation and PPARγ-pERK protein complex increase (Jahrling et al. 2014) . We found analogous effects on PPARγ-pERK protein complexes induced by the cue reactivity test in PFC and HIP. Taken together, these data support our fundamental hypothesis that, in behaviors and cognitive tasks in which ERK is pivotal, PPARγ may serve as an intermediary to resurrect proper ERK function.
Finally, a series of supportive experiments provided additional evidence that PPARγ agonism is a valid therapeutic approach for protection against maladaptive plasticity resulting from chronic cocaine versus a natural reward, e.g. sucrose. In addition, we found that PPARγ agonism blocked the development of behavioral sensitization while having no effect on the acquisition of sucrose SA or cue reactivity similar to previous work (Stopponi et al. 2011) . The fact that our biochemical studies tracked with the behavioral outcomes on sucrose SA and previously active lever pressing, in that sucrose cue reactivity tests induced no differences in nuclear PPARγ or pERK, are consistent with our overall postulate that PPARγ Figure 6 pERK:PPARγ protein complexes are increased by exposure to cues related to cocaine self-administration in PIO-treated rats; PPARγ antagonism reversed effects of PIO treatment. Immunoprecipitation of PPAR from (a) PFC and (b) HIP demonstrates that PIO treatment promotes the formation of pERK-PPARγ complexes following exposure to cues related to cocaine SA (white bars) that is blocked by GW9662. Two-way ANOVA F(1,31) = 11.3 and 9.94, p = 0.002 and 0.007 for PFC and HIP, respectively. *p < 0.05 compared to all other groups, Tukey pairwise analysis. Data expressed as mean +/À SEM agonism alters the behavioral and biochemical landscape in which ERK is dysregulated and an essential mediator of said behaviors (Denner et al. 2012; Jahrling et al. 2014) .
In summary, these studies support our hypothesis that PPARγ agonism attenuates cocaine-seeking behavior via pERK-dependent mechanisms within limbiccorticostriatal brain regions that underlie drug dependence. Thus, PPARγ represents a viable therapeutic target for the prevention of relapse to cocaine abuse; as PIO is a FDA approved ligand, ongoing studies include a small placebo-controlled clinical trial in which cocainedependent subjects are treated with PIO and cocaine cue reactivity and cocaine-positive urine is monitored (NIH clinicaltrials.gov identifier: NCT02774343). We expect that the novel role that PPARγ agonism plays in reigning in dysregulated ERK function will have applicability to cognitive aging, aging-related neurodegenerative disease, as well as addiction.
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